Education
About Us
Working with TipRanks
Follow Us
KALA BIO (KALA)
NASDAQ:KALA
KALA Stock Chart & Stats
$0.97
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.97
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.61 - $20.60
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$5.28M
Enterprise Value$28.99M
Total Cash (Recent Filing)$21.10M
Total Debt (Recent Filing)$29.94M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 26, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding7,021,040
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap5.49
Enterprise Value/Revenue114.14
Enterprise Value/Gross Profit-3.62K
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$1.50Price Target Upside54.64% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst reiterates Buy rating and raises the 12-month price target to $35 per share, reflecting increased confidence in KPI-012's potential.
Clinical Trial SuccessThe Phase 1b trial of KPI-012 showed rapid healing with 75% of patients experiencing complete healing of PCED after 4 weeks.
Market OpportunityWith no FDA approved treatment for PCED, KPI-012 could unlock real commercial potential.
Bears Say
Clinical Trial FailureThe CHASE trial of KPI-012 did not meet the primary endpoint of complete healing of PCED and failed to achieve statistical significance for key secondary efficacy endpoints.
Financial InstabilityThere is approximately one year of cash left given the current annualized cash burn.
Strategic ChallengesManagement decided to cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform due to the trial results.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.61 and its highest was $20.60 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $5.28M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Mar 26, 2026 which is in 115 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on Nov 17, 2025. The company reported -$1.01 earnings per share for the quarter, the consensus estimate of -$1.01 by $0.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Undervalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate is -0.32.
How many shares outstanding does KALA BIO have?
KALA BIO has 7,021,040 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$1.01 in its last earnings report, expectations of -$1.01. Following the earnings report the stock price went down -1.408%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
Company Description
KALA BIO
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. The company primarily operates within the healthcare sector, specializing in ophthalmology. Its core products are designed to address unmet needs in ocular health, including treatments for dry eye disease and inflammation following ocular surgery.
KALA Stock 12 Month Forecast
Average Price Target
$1.50
▲(54.64% Upside)
Technical Analysis
Ownership Overview
10.52% Insiders
3.10% Mutual Funds
19.78% Other Institutional Investors
63.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---